Diltiazem - CAS 42399-41-7
Catalog number: 42399-41-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H26N2O4S
Molecular Weight:
414.52
COA:
Inquire
Targets:
Calcium Channel
Description:
Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia as a potent vasodilator, increasing blood flow and variably decreasing the heart rate via strong depression of A-V node conduction.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥95%
Appearance:
Solid powder
Synonyms:
Cardizem; D-cis-Diltiazem; [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
A nondihydropyridines (non-DHP) calcium channel blocker
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
Density:
1.26 g/cm3
InChIKey:
HSUGRBWQSSZJOP-RTWAWAEBSA-N
InChI:
1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
Canonical SMILES:
CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
1.Twenty-Four-Hour Urine α1 -Microglobulin as a Marker of Hypertension-Induced Renal Impairment and Its Response on Different Blood Pressure-Lowering Drugs.
Liakos CI1, Vyssoulis GP1, Markou MI1, Kafkas NV2, Toutouzas KP1, Tousoulis D1. J Clin Hypertens (Greenwich). 2016 Mar 18. doi: 10.1111/jch.12811. [Epub ahead of print]
The purpose of this study was to assess the role of urine α1 -microglobulin as a marker of hypertension-induced renal damage compared with estimated glomerular filtration rate, (eGFR), urine albumin, and urine albumin-to-creatinine ratio (ACR). Its response on different blood pressure (BP)-lowering drugs was also studied. Sixty never-treated hypertensive patients (65.0% men, 46.9 years, BP 141.4/94.0 mm Hg) were randomized to an irbesartan (an angiotensin receptor blocker [ARB]) or a diltiazem (a nondihydropyridine calcium channel blocker [CCB])-based regimen. Patients with diabetes or established cardiovascular, renal, or liver disease were excluded. Blood samples and 24-hour urine were analyzed at baseline and 6 months after pharmaceutical BP normalization. Serum creatinine was measured and eGFR was calculated. Urine albumin, creatinine, and α1 -microglobulin were measured and ACR was calculated. Minor changes (P=not significant [NS]) in eGFR were noted during follow-up in both groups (from 111.
2.Predicted and observed therapeutic dose exceedances of ionizable pharmaceuticals in fish plasma from urban coastal systems.
Scott WC1, Du B1, Haddad SP1, Breed CS1, Saari GN1, Kelly M2, Broach L2, Chambliss CK1,3, Brooks BW1. Environ Toxicol Chem. 2016 Apr;35(4):983-95. doi: 10.1002/etc.3236. Epub 2016 Jan 19.
Instream flows of the rapidly urbanizing watersheds and estuaries of the Gulf of Mexico in Texas (USA) are increasingly dominated by reclaimed waters. Though ionizable pharmaceuticals have received increasing attention in freshwaters, many research questions remain unanswered, particularly in tidally influenced urban coastal systems, which experience significant spatiotemporal variability in pH that influences bioavailability and bioaccumulation. The authors coupled fish plasma modeling of therapeutic hazard values with field monitoring of water chemistry variability and pharmaceutical occurrence to examine whether therapeutic hazards to fish existed within these urban coastal ecosystems and whether therapeutic hazards differed within and among coastal locations and seasons. Spatial and temporal fluctuations in pH within study sites altered the probability of encountering pharmaceutical hazards to fish. Significant water quality differences were consistently observed among traditional parameters and pharmaceuticals collected from surface and bottom waters, which are rarely sampled during routine surface water quality assessments.
3.Regression of Calcium Channel Blocker--Induced Gingival Enlargement in the Absence of Periodontal Therapy.
Livada R, Shelton W, Bland PS, Shiloal J. J Tenn Dent Assoc. 2015 Fall-Winter;95(2):11-4; quiz 15-6.
AIM: To illustrate the negative effect of calcium channel blocker (CCB) drugs on the gingival tissues and the reversibility of these lesions.
4.Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases.
Rodríguez Padial L1, Barón-Esquivias G2, Hernández Madrid A3, Marzal Martín D4, Pallarés-Carratalá V5,6, de la Sierra A7. Cardiol Ther. 2016 Mar 25. [Epub ahead of print]
Cardiovascular diseases are the leading cause of death in the world. Coronary artery diseases, atrial fibrillation or hypertensive heart disease, are among the most important cardiovascular disorders. Hypertension represents a significant risk factor for cardiovascular mortality; thus, control of high blood pressure has become a priority to prevent major complications. Although the choice of drugs for treating hypertension remains controversial, extensive clinical evidences point to calcium channel blockers as first-line agents. Diltiazem, a non-dihydropyridine calcium channel blocker, is an effective and safe antihypertensive drug, alone or in combination with other agents. Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility, representing also a good alternative for the treatment of stable chronic angina. Furthermore, diltiazem reduces conduction in atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Calcium Channel Products


CAS 33286-22-5 Diltiazem Hydrochloride

Diltiazem Hydrochloride
(CAS: 33286-22-5)

Diltiazem HCl (Tiazac) is a benzothiazepine derivative with vasodilating action due to its antagonism of the actions of the calcium ion in membrane functions.

CAS 77-67-8 Ethosuximide

Ethosuximide
(CAS: 77-67-8)

Ethosuximide is a Calcium channel antagonist originated by Pfizer. It can be used for the treatment of Absence epilepsy and absence seizures. It may be used by ...

CAS 72509-76-3 Felodipine

Felodipine
(CAS: 72509-76-3)

Felodipine is a selective L-type Ca2+ channel blocker with IC50 of 0.15 nM. It can lower blood pressure by reducing peripheral vascular resistance via a highly ...

CAS 136-47-0 Tetracaine Hydrochloride

Tetracaine Hydrochloride
(CAS: 136-47-0)

Tetracaine hydrochlorideis a hydrochloride salt form of tetracaine which is a potent local anaesthetic and a channel function allosteric inhibitor.

CAS 357400-13-6 NNC 55-0396 dihydrochloride

NNC 55-0396 dihydrochloride
(CAS: 357400-13-6)

NNC 55-0396 is a derivative of Mibefradil as a T-type calcium channel blocker (IC50=6.8 nM)

CAS 42399-41-7 Diltiazem

Diltiazem
(CAS: 42399-41-7)

Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the treatment of hypertension, angina pectoris, and some types of arrhythmia as a p...

CAS 75695-93-1 Isradipine

Isradipine
(CAS: 75695-93-1)

Isradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.

CAS 68291-98-5 Zonisamide sodium salt

Zonisamide sodium salt
(CAS: 68291-98-5)

Zonisamide is the first agent of this chemical class to be developed as an antiepileptic drug blocks repetitive firing of voltagesensitive sodium channels and r...

CAS 89226-50-6 Manidipine

Manidipine
(CAS: 89226-50-6)

Manidipine is a dihydropyridine calcium antagonist with an IC50 of 2.6 nM.

CAS 116644-53-2 Mibefradil

Mibefradil
(CAS: 116644-53-2)

Mibefradil, a calcium channel blocker, has modest selectivity for T-type Ca2+ channels so that could be used in the treatment of sorts of cardiovascular disease...

CAS 79700-61-1 Dopropidil

Dopropidil
(CAS: 79700-61-1)

Dopropidil, also called as ORG 30701, is a cardioactive drug to be classified as a calcium antagonist with combined class I and class VI antiarrhythmic properti...

CAS 41332-24-5 NP-118809

NP-118809
(CAS: 41332-24-5)

NP-118809 is a N-type calcium channel blocker exhibits both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain...

CAS 150493-34-8 NS-638

NS-638
(CAS: 150493-34-8)

NS-638 is a small nonpeptide Ca(2+)-channel blocker.

CAS 103890-78-4 Lacidipine

Lacidipine
(CAS: 103890-78-4)

Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker. Lacidipine (Lacipil, Motens) works by relaxing and opening up the blood vessels.

CAS 13636-18-5 Fendiline hydrochloride

Fendiline hydrochloride
(CAS: 13636-18-5)

The hydrochloride salt form of Fendiline, a benzenepropanamine derivative, has been found to be a calcium channel blocker and alpha2-adrenergic receptor antagon...

CAS 88150-42-9 Amlodipine

Amlodipine
(CAS: 88150-42-9)

Amlodipine is a long-acting calcium channel blocker, used to lower blood pressure and prevent chest pain.

CAS 52468-60-7 Flunarizine

Flunarizine
(CAS: 52468-60-7)

Flunarizine is a selective calcium entry blocker, which has calmodulin binding properties and histamine H1 blocking activity. It may help to reduce the severity...

CAS 30484-77-6 Flunarizine Dihydrochloride

Flunarizine Dihydrochloride
(CAS: 30484-77-6)

Flunarizine 2HCl is a dihydrochloride salt form which is a calcium channel blocker with a Ki of 68 nM.

CAS 54527-84-3 Nicardipine Hydrochloride

Nicardipine Hydrochloride
(CAS: 54527-84-3)

Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders.

CAS 116666-63-8 Mibefradil dihydrochloride hydrate

Mibefradil dihydrochloride hydrate
(CAS: 116666-63-8)

The dihydrochloride hydrate salt form of Mibefradil which is a calcium channel blocker with modest selectivity for T-type Ca2+ channels so that it could be used...

Chemical Structure

CAS 42399-41-7 Diltiazem

Quick Inquiry

Verification code

Featured Items